tradingkey.logo


Viatris Inc

VTRS
11.930USD
-0.010-0.08%
āļ›āļīāļ” 12/19, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
13.83BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Viatris Inc āļšāļĢāļīāļĐāļąāļ—

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.

āļ‚āđ‰āļ­āļĄāļđāļĨ Viatris Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VTRS
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Viatris Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļFeb 01, 1973
āļ‹āļĩāļ­āļĩāđ‚āļ­Smith (Scott A)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™32000
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Feb 01
āļ—āļĩāđˆāļ­āļĒāļđāđˆ1000 Mylan Boulevard
āđ€āļĄāļ·āļ­āļ‡CANONSBURG
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ15317
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ17245141465
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.viatris.com/en
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VTRS
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļFeb 01, 1973
āļ‹āļĩāļ­āļĩāđ‚āļ­Smith (Scott A)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Viatris Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Rajiv Malik
Mr. Rajiv Malik
Director
Director
1.07M
--
Mr. Paul B. Campbell
Mr. Paul B. Campbell
Chief Accounting Officer, Corporate Controller
Chief Accounting Officer, Corporate Controller
254.46K
--
Mr. Brian Roman
Mr. Brian Roman
Chief Legal Officer
Chief Legal Officer
193.92K
--
Mr. Richard A. Mark, CPA
Mr. Richard A. Mark, CPA
Independent Director
Independent Director
91.31K
--
Mr. Wyllie Don Cornwell
Mr. Wyllie Don Cornwell
Independent Director
Independent Director
80.34K
--
Ms. Elisha W. Finney
Ms. Elisha W. Finney
Independent Director
Independent Director
37.83K
--
Ms. Theodora (Doretta) Mistras
Ms. Theodora (Doretta) Mistras
Chief Financial Officer
Chief Financial Officer
25.18K
--
Ms. JoEllen Lyons Dillon
Ms. JoEllen Lyons Dillon
Independent Director
Independent Director
--
--
Mr. Mark W. Parrish
Mr. Mark W. Parrish
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Melina E. Higgins
Ms. Melina E. Higgins
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Rajiv Malik
Mr. Rajiv Malik
Director
Director
1.07M
--
Mr. Paul B. Campbell
Mr. Paul B. Campbell
Chief Accounting Officer, Corporate Controller
Chief Accounting Officer, Corporate Controller
254.46K
--
Mr. Brian Roman
Mr. Brian Roman
Chief Legal Officer
Chief Legal Officer
193.92K
--
Mr. Richard A. Mark, CPA
Mr. Richard A. Mark, CPA
Independent Director
Independent Director
91.31K
--
Mr. Wyllie Don Cornwell
Mr. Wyllie Don Cornwell
Independent Director
Independent Director
80.34K
--
Ms. Elisha W. Finney
Ms. Elisha W. Finney
Independent Director
Independent Director
37.83K
--

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāļ—āļĩāđˆ 6 āļ•.āļ„.
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Brands
2.28B
64.01%
Generics
1.28B
35.99%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Developed markets
2.12B
59.38%
Greater China
588.90M
16.50%
Emerging Markets
555.10M
15.55%
JANZ
305.70M
8.57%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Brands
2.28B
64.01%
Generics
1.28B
35.99%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 16 āļž.āļĒ.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 16 āļž.āļĒ.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
12.14%
T. Rowe Price Associates, Inc.
7.13%
Davis Selected Advisers, L.P.
6.02%
BlackRock Institutional Trust Company, N.A.
5.31%
State Street Investment Management (US)
4.84%
āļ­āļ·āđˆāļ™ āđ†
64.56%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
12.14%
T. Rowe Price Associates, Inc.
7.13%
Davis Selected Advisers, L.P.
6.02%
BlackRock Institutional Trust Company, N.A.
5.31%
State Street Investment Management (US)
4.84%
āļ­āļ·āđˆāļ™ āđ†
64.56%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
44.04%
Investment Advisor/Hedge Fund
28.24%
Hedge Fund
8.77%
Research Firm
2.71%
Pension Fund
1.29%
Sovereign Wealth Fund
1.01%
Bank and Trust
0.85%
Individual Investor
0.27%
Family Office
0.06%
āļ­āļ·āđˆāļ™ āđ†
12.75%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļļāļ˜āļ—āļĩāđˆ 1 āļ•.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q3
1934
987.12M
85.35%
-46.41M
2025Q2
1947
984.91M
83.97%
-87.31M
2025Q1
2006
1.01B
85.93%
-61.76M
2024Q4
2002
1.03B
86.53%
+1.20M
2024Q3
1949
989.28M
82.89%
-66.19M
2024Q2
1967
1.02B
85.33%
-16.59M
2024Q1
1986
997.86M
84.00%
-35.39M
2023Q4
2032
990.53M
82.57%
-31.15M
2023Q3
2044
970.48M
80.90%
-45.34M
2023Q2
2080
963.51M
80.35%
-35.04M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
The Vanguard Group, Inc.
144.70M
12.41%
+694.66K
+0.48%
Jun 30, 2025
T. Rowe Price Associates, Inc.
76.96M
6.6%
+4.28M
+5.89%
Jun 30, 2025
Davis Selected Advisers, L.P.
66.38M
5.69%
+1.43M
+2.20%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
61.38M
5.26%
-2.94M
-4.57%
Jun 30, 2025
State Street Investment Management (US)
55.29M
4.74%
-6.17M
-10.04%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
31.26M
2.68%
+10.00M
+47.05%
Jun 30, 2025
Geode Capital Management, L.L.C.
31.23M
2.68%
+52.78K
+0.17%
Jun 30, 2025
Columbia Threadneedle Investments (US)
22.77M
1.95%
+1.16M
+5.38%
Jun 30, 2025
Deerfield Management Company, L.P.
24.02M
2.06%
+32.31K
+0.13%
Jun 30, 2025
Invesco Capital Management LLC
24.15M
2.07%
+928.68K
+4.00%
Jun 30, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
iShares U.S. Pharmaceuticals ETF
4.46%
First Trust NASDAQ Pharmaceuticals ETF
3.81%
Davis Select Worldwide ETF
3.62%
Davis Select US Equity ETF
3.36%
Invesco Pharmaceuticals ETF
2.66%
State Street SPDR S&P Pharmaceuticals ETF
2.64%
Invesco S&P Ultra Dividend Revenue ETF
2.56%
Alps Sector Dividend Dogs ETF
2.1%
AAM S&P 500 High Dividend Value ETF
1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.88%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
iShares U.S. Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™4.46%
First Trust NASDAQ Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.81%
Davis Select Worldwide ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.62%
Davis Select US Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.36%
Invesco Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.66%
State Street SPDR S&P Pharmaceuticals ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.64%
Invesco S&P Ultra Dividend Revenue ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.56%
Alps Sector Dividend Dogs ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.1%
AAM S&P 500 High Dividend Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.95%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.88%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 2.13B USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
Nov 04, 2025
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 15, 2025 going ex on Nov 24, 2025
Nov 24, 2025
Dec 15, 2025
Nov 24, 2025
Aug 05, 2025
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 15, 2025 going ex on Aug 22, 2025
Aug 22, 2025
Sep 15, 2025
Aug 22, 2025
May 07, 2025
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Jun 16, 2025 going ex on May 23, 2025
May 23, 2025
Jun 16, 2025
May 23, 2025
Feb 27, 2025
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Mar 18, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 18, 2025
Mar 10, 2025
Nov 05, 2024
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 13, 2024 going ex on Nov 22, 2024
Nov 22, 2024
Dec 13, 2024
Nov 22, 2024
Aug 06, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 13, 2024 going ex on Aug 23, 2024
Aug 23, 2024
Sep 13, 2024
Aug 23, 2024
May 09, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Jun 14, 2024 going ex on May 23, 2024
May 24, 2024
Jun 14, 2024
May 23, 2024
Feb 28, 2024
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Mar 18, 2024 going ex on Mar 08, 2024
Mar 11, 2024
Mar 18, 2024
Mar 08, 2024
Nov 08, 2023
VTRS.NB Final Cash Dividend of gross USD 0.12 paid on Dec 15, 2023 going ex on Nov 22, 2023
Nov 24, 2023
Dec 15, 2023
Nov 22, 2023
Aug 07, 2023
VTRS.NB Interim Cash Dividend of gross USD 0.12 paid on Sep 15, 2023 going ex on Aug 23, 2023
Aug 24, 2023
Sep 15, 2023
Aug 23, 2023
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Viatris Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Viatris Inc āđ„āļ”āđ‰āđāļāđˆ:
The Vanguard Group, Inc. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 144.70M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 12.41% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
T. Rowe Price Associates, Inc. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 76.96M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 6.60% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
Davis Selected Advisers, L.P. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 66.38M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 5.69% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
BlackRock Institutional Trust Company, N.A. āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 61.38M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 5.26% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”
State Street Investment Management (US) āļ–āļ·āļ­āļ„āļĢāļ­āļ‡āļŦāļļāđ‰āļ™āļˆāļģāļ™āļ§āļ™ 55.29M āļŦāļļāđ‰āļ™ āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 4.74% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ”

āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Viatris Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŠāļēāļĄāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Viatris Inc āđ„āļ”āđ‰āđāļāđˆ
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
Davis Selected Advisers, L.P.

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Viatris Inc (VTRS)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2025Q3 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 1934 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Viatris Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 987.12M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 85.35% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q2 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ 1.37%

āđāļŦāļĨāđˆāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŦāļĨāļąāļāļ‚āļ­āļ‡ Viatris Inc āļ„āļ·āļ­āļ­āļ°āđ„āļĢ?


āđ€āļĄāļ·āđˆāļ­āļ§āļąāļ™āļ—āļĩāđˆ FY2025Q2 āļ˜āļļāļĢāļāļīāļˆāļ”āđ‰āļēāļ™ Brands āļŠāļĢāđ‰āļēāļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļŠāļđāļ‡āļŠāļļāļ”āđƒāļŦāđ‰āļāļąāļš Viatris Inc āļ„āļīāļ”āđ€āļ›āđ‡āļ™āļĄāļđāļĨāļ„āđˆāļē 2.28B āđāļĨāļ°āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 64.01% āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰āļĢāļ§āļĄ
KeyAI
î™